Phase 2 Cystic Fibrosis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Adults aged between 18 and 85 years old.
• People who have been diagnosed with non-cystic fibrosis bronchiectasis (a lung condition where the airways are permanently widened), confirmed by a chest CT scan reviewed by a radiologist — a scan from within the past 12 months is acceptable, or one will be arranged during the screening period if needed.
• People who have had at least 2 lung infection flare-ups in the past year that required antibiotic treatment (by mouth or through a drip), OR at least 1 such flare-up plus a score above 40 on a specific respiratory symptom questionnaire given during screening.
• People already taking certain long-term lung medications (such as macrolide antibiotics or DPP-1 inhibitors) may still be eligible, provided at least 1 flare-up occurred while they had been on a stable dose of that medication for 3 months or more.
• People whose lungs are functioning above a certain level, based on a breathing test done during screening — specifically, a post-bronchodilator FEV1 above 35% of the predicted normal value and at least 1 litre in volume (confirm with trial site if unsure what this means for a specific situation).

Who may not be able to join:

• People who have previously experienced airway spasms or breathing problems in response to inhaled treatments, including inhaled antibiotics.
• People with a known or suspected allergy or severe reaction to the study drug, any of its ingredients, or to immunoglobulin-based medicines.
• People whose primary lung diagnosis is a condition other than non-cystic fibrosis bronchiectasis, such as COPD, asthma, or diffuse panbronchiolitis, as determined by the treating doctor.
• People who have had a lung infection flare-up requiring antibiotic treatment within the 4 weeks before the study baseline visit.

Important: Always verify eligibility with the trial site directly before applying.